59937-01-8

Basic information

• Product Name: RARECHEM AL BI 1318
• Synonyms: RARECHEM AL BI 1318;2-PHENYL-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER;4-THIAZOLECARBOXYLIC ACID, 2-PHENYL-, ETHYL ESTER;ethyl 2-phenylthiazole-4-carboxylate
• CAS NO: 59937-01-8
• Molecular Formula: C₁₂H₁₁NO₂S
• Molecular Weight: 233.29
• Mol File: 59937-01-8.mol
• Article Data: 32

Chemical Properties

• Melting Point: 47 °C
• Boiling Point: 365℃
• Flash Point: 175℃
• Appearance: /
• Density: 1.216
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 0.09±0.10(Predicted)
• CAS DataBase Reference: RARECHEM AL BI 1318(CAS DataBase Reference)
• NIST Chemistry Reference: RARECHEM AL BI 1318(59937-01-8)
• EPA Substance Registry System: RARECHEM AL BI 1318(59937-01-8)

Safety Data

• Hazardous Substances Data: 59937-01-8(Hazardous Substances Data)

Usage

General Description

RARECHEM AL BI 1318 is a chemical compound that is a mixture of aluminum bis(2-ethylhexanoate) and mineral spirits. It is used as a catalyst in the production of polyurethanes, as well as in the manufacturing of coatings, adhesives, sealants, and elastomers. The aluminum component of RARECHEM AL BI 1318 acts as a Lewis acid catalyzer, promoting the reaction between isocyanates and polyols to form polyurethane. The mineral spirits component acts as a solvent, aiding in the application and dispersion of the compound in various manufacturing processes. RARECHEM AL BI 1318 is a versatile and widely used chemical in the production of many industrial products.

Upstream product

• 70-23-5 ethyl Bromopyruvate 
• 2227-79-4 benzenecarbothioamide 
• 189228-43-1 (2RS,4R)-2-phenylthiazolidine-4-carboxylic acid ethyl ester 
• 14214-10-9 ethyl diazopyruvate 
• 425392-44-5 2-bromo-5-chlorothiazole-4-carboxylic acid ethyl ester 
• 98-80-6 phenylboronic acid 
• 673476-96-5 (2-chloro-phenyl)-thioacetic acid amide 
• 3411-58-3 L-cystein ethyl ester 
• 100-52-7 benzaldehyde 
• 89530-19-8 ethyl (4R)-2-phenyl-4,5-dihydrothiazole-4-carboxylate 
• 37128-20-4 4-hydroxy-2-phenyl-4,5-dihydro-thiazole-4-carboxylic acid ethyl ester 
• 70454-09-0 Ethyl 5,5-dihydro-2-phenyl-2-thiazoline-4-carboxylate 
• 1499-53-2 ethyl hippurate 
• 80548-05-6 2-benzoylamino-3-oxo-propionic acid ethyl ester 

Downstream Products

• 7113-10-2 2-phenyl-1,3-thiazole-4-carboxylic acid 
• 857550-21-1 2-phenyl-1,3-thiazole-4-carboxamide 
• 7113-12-4 2-phenyl-1,3-thiazole-4-carboxylic acid hydrazide 
• 85318-72-5 methyl 3-(2-phenylthiazole-4-carboxamido)propyl sulfide 
• 23780-13-4 (2-phenylthiazol-4-yl)methanol 
• 36094-04-9 2-phenyl-1,3-thiazole-4-carboxylic acid chloride 
• 799283-96-8 4-isocyanato-2-phenyl-thiazole 
• 400775-03-3 2-phenyl-thiazole-4-carbonyl azide 
• 7113-11-3 (2-phenyl-thiazol-4-yl)-carbamic acid methyl ester 
• 7171-34-8 2-Phenyl-4-acetoamidothiazole 
• 7113-02-2 2-phenyl-1,3-thiazole-4-carboxylic acid methyl ester 
• 7113-05-5 2-phenyl-1,3-thiazole-4-carbonitrile 
• 7113-14-6 2-phenylthiazole-4-carbothioamide 
• 914347-21-0 ethyl 5-bromo-2-phenylthiazole-4-carboxylate 

Relevant articles and documents

Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family

Bromodomain and extra-terminal (BET) is a promising therapeutic target for various hematologic cancers. We used the BRD4 inhibitor compound 13 as a lead compound to develop a variety of compounds, and we introduced diverse groups into the position of the compound 13 orienting toward the ZA channel. A series of compounds (14–23, 38–41, 43, 47–49) bearing triazolopyridazine motif exhibited remarkable BRD4 protein inhibitory activities. Among them, compound 39 inhibited BRD4(BD1) protein with an IC50 of 0.003 μM was superior to lead compound 13. Meanwhile, compound 39 possess activity, IC50 = 2.1 μM, in antiproliferation activity against U266 cancer cells. On the other hand, compound 39 could arrest tumor cells into the G0/G1 phase and induce apoptosis, which was consistent with its results in inhibiting cell proliferation. Biological and biochemical data suggest that BRD4 protein might be a therapeutic target and that compound 39 is an excellent lead compound for further development.

INHIBITORS OF HUMAN ATGL

The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.

Discovery of 2-phenylthiazole-4-carboxylic acid, a novel and potent scaffold as xanthine oxidase inhibitors

The xanthine oxidase (XO) plays an important role in producing uric acid, and therefore XO inhibitors are considered as one of the promising therapies for hyperuricemia and gout. We have previously reported a series of XO inhibitors with pyrazole scaffold to extend the chemical space of current XO inhibitors. Herein, we describe further structural optimization to explore the optimal heterocycle by replacing the thiazole ring of Febuxostat with 5 heterocycle scaffolds unexplored in this field. All of these efforts resulted in the identification of compound 8, a potent XO inhibitor (IC50 = 48.6 nM) with novel 2-phenylthiazole-4-carboxylic acid scaffold. Moreover, lead compound 8 exhibited hypouricemic effect in potassium oxonate-hypoxanthine-induced hyperuricemic mice. These results promote the understanding of ligand-receptor interaction and might help to design more promising XO inhibitors.